Additionally, we found that targeting Fli-1 using low-dose CPT or ETO was an effective strategy to reduce aGVHD severity and lethality after allo-BMT, while preserving the ability of alloreactive T cells to prevent leukemia relapse. The gene discussed is FLI1; the disease is leukemia.